– USA, CA – Applied BioCode (TSE: 6598) today announced the appointment of Chris Bernard as CEO.
“With his fresh perspective and leadership, Chris will work closely with Dr. Ho to deliver on the company’s global strategy and mission as a molecular diagnostics company, through product development, commercialization, and strategic alliances.” said Board Chairman, Dr. George Lee.
About Chris Bernard
Chris Bernard joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. With its current portfolio of PCR-based, multiplex molecular diagnostic tests in the respiratory and gastrointestinal markets, along with the new SARS-CoV-2 Flu Plus Assay EUA approval, the company is continuing to scale its commercial business in providing transformative solutions for high throughput molecular diagnostics.
Chris Bernard brings 27 years of strong commercial, operational, and R&D leadership experience in diagnostics and medical devices to Applied BioCode. Most recently Chris was CEO of Oncogenesis Inc., a startup in oncology diagnostics, and Curetis USA Inc., (Opgen Inc.), a multiplex, infectious disease diagnostic company. He also has held various commercial executive roles at Epic Sciences Inc., Metabolon Inc., Abaxis Inc. (Zoetis Inc.), and Cytyc Corp (Hologic Inc.). His extensive experience will be key in evaluating current and emerging opportunities as the company enters its next phase of commercial expansion.
“The Applied BioCode team has developed a really innovative, multiplex PCR-based technology and the platform is uniquely positioned in the marketplace. I look forward to leading the company into our next phase of growth and long-term success. I am also excited to collaborate with Dr. Winston Ho, President, and the Board of Directors as we execute on the vision of delivering a cost-effective diagnostic platform that is designed to optimize workflow and alleviate pain points for mid to high-throughput PCR labs,” said Chris Bernard.
About Applied BioCode
Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products. The company has combined “digital barcodes” with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Bead Technology. The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets. The company has FDA 510(k) clearances for their 17-plex Respiratory Pathogen Panel and 17-plex Gastrointestinal Pathogen Panel based on their BioCode MDx-3000 automated system. The GPP and RPP are CE-Marked for use in European countries conforming to CE-Mark regulations. Applied BioCode, Inc. has also been granted an Emergency Use Authorization from the U.S. FDA for its BioCode SARS-CoV-2 Flu Plus Assay**, BioCode SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*. Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.
For more information: https://apbiocode.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.